We conducted a phase I #clinicaltrial with CoVac-1, our #peptide-based #COVID19#vaccine candidate for induction of SARS-CoV-2 T cell immunity. Our observations support the presently ongoing phase II trial for patients with B cell/antibody deficiency. Here’s what we found:
Very proud that @JulianeWalz received this years best abstract award at the @dgho_eV for her presentation on our peptide-based #COVID19#vaccine for patients affected by antibody shortage
Two exciting talks were held by our lab members @mroerden1 and Jens Bauer on #Covid_19#tcell responses in #Cancer patients and a new fusion protein as potential immunotherapeutic target for the treatment of FLHCC at this years @dgho_eV meeting
Check out our latest preprint: This first comprehensive analysis of #SARS_CoV_2 immune responses in #cancer patients reports on the implications of impaired SARS-CoV-2 T cell responses for understanding pathophysiology and predicting severity of #COVID19 https://t.co/D0e35nKGjr
We are starting a phase-I #clinicaltrial for our peptide #vaccine against chronic lymphocytic leukemia (CLL). The aim is to avoid relapse due to minimal residual disease after first line therapy with Ibrutinib. @uktuebingen
https://t.co/rzsXlUD2HT
Very happy and excited that one of our publications is among the 5 most popular scientific papers in the Nature Index journals #sciencetwitter#SARS_CoV_2
Check out our latest review "The peptide #vaccine of the future" by @AnnikaNel published in @molcellprot
https://t.co/Zy86fM8Xh0
https://t.co/VwwqifJe9V
Check out the online preprint on our work defining #SARSCoV2 T-cell epitopes
SARS-CoV-2 T-cell epitopes define heterologous and COVID-19-induced T-cell recognition https://t.co/nvMFRyyIah